ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0399

A Heavy Burden of Calcinosis Reflects Cumulative Disease Damage in Scleroderma

Carrie Richardson1, Jamie Perin2, Scott Zeger3, Fredrick Wigley4, Laura Hummers5, Livia Casciola-Rosen6, Antony Rosen7 and Ami Shah8, 1Rush University Medical Center, Chicago, IL, 2JHUSPH, Baltimore, 3Johns Hopkins University, Baltimore, 4Johns Hopkins University School of Medicine, Baltimore, MD, 5Johns Hopkins Univerisity, Ellicott City, MD, 6Johns Hopkins University, Johns Hopkins University, MD, 7Johns Hopkins University, Baltimore, MD, 8Johns Hopkins University School of Medicine, Ellicott City, MD

Meeting: ACR Convergence 2020

Keywords: Biomarkers, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Systemic Sclerosis & Related Disorders – Clinical Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Ectopic calcification, or calcinosis, is a common complication of scleroderma. However, a subset of scleroderma patients has a heavy burden of calcinosis, which may have unique risk factors compared to a light burden of calcinosis.

Methods: We determined calcinosis burden of patients in the Johns Hopkins Scleroderma Center cohort database through chart review. A heavy burden was defined as calcinosis deposits in three or more body areas excluding the hands and fingers, mass-like or bulky deposits, and/or sheet-like or plaque-like deposits on physician exam. A light burden was defined as calcinosis present but not meeting the criteria for heavy burden by chart review.  No calcinosis was defined as calcinosis recorded as absent in the Scleroderma Center database. We performed exploratory analyses comparing clinical, demographic, and serologic parameters by burden status. We then performed latent class analysis to identify scleroderma phenotypic classes followed by multinomial logistic regression to determine whether latent phenotypic classes and autoantibodies are independent risk factors for a light burden or a heavy burden of calcinosis.

Results: 29.4% (997/3388) of patients with scleroderma had calcinosis. 13.5% (130/963) had a heavy burden. The phenotypic class (Class 3 in Table 1) with predominantly diffuse skin disease as well as the greatest overall disease severity was associated with an increased risk of both a heavy burden of calcinosis (OR 6.29, 95% CI 3.42-11.57; p< 0.001) and a light burden of calcinosis (OR 2.71, 95% CI 2.01-3.65; p< 0.001) compared to the reference class with predominantly limited skin disease (Class 4).  The phenotypic class with predominantly sine skin disease (Class 1) was associated with a decreased risk of a light burden of calcinosis (OR 0.26, 95% CI 0.16-0.42; p< 0.001) compared to Class 4 but was not significantly associated with a high burden.  The phenotype with predominantly diffuse skin disease but less severe extra-cutaneous disease compared to Class 3 (Class 2) was not associated with either a light or heavy burden of calcinosis.  Autoantibodies to PM100 (OR 4.04, 95% CI 1.53 to 10.68; p=0.005) and PM75 (OR 3.07, 95% CI 1.23 to 7.68; p=0.024) were associated with an increased risk of a heavy burden of calcinosis.

Conclusion: Calcinosis burden may reflect cumulative scleroderma-related tissue damage. Independent of disease activity, autoantibodies to the PM/Scl complex are associated with a high burden of calcinosis, indicating the possibility of excess subclinical disease activity or aberrant tissue repair in patients with this unique immunologic response.


Disclosure: C. Richardson, None; J. Perin, None; S. Zeger, None; F. Wigley, None; L. Hummers, Corbus Pharmaceuticals, 1, 2, Boehringer Ingelheim, 1, 2, CSL Behring, 1, 2, Cumberland Pharmaceuticals, 1, Medpace, 1, Glaxo Smith Kline, 1, Kadmon Corporation, 1; L. Casciola-Rosen, None; A. Rosen, Inova, 7, Celgene, 7; A. Shah, None.

To cite this abstract in AMA style:

Richardson C, Perin J, Zeger S, Wigley F, Hummers L, Casciola-Rosen L, Rosen A, Shah A. A Heavy Burden of Calcinosis Reflects Cumulative Disease Damage in Scleroderma [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/a-heavy-burden-of-calcinosis-reflects-cumulative-disease-damage-in-scleroderma/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-heavy-burden-of-calcinosis-reflects-cumulative-disease-damage-in-scleroderma/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology